News Posts List
Treatment of Metastatic Disease
06/07/2012
This review discusses current targeted therapies for mRCC and provides consensus statements regarding treatment algorithms.
Outcomes Following Surgical Management of Localised Renal Cancer
06/07/2012
Systematically review relevant literature comparing oncological outcomes of surgical management of localised RCC (T1–2N0M0).
Treatment of Localised Renal Cell Carcinoma
06/07/2012
The increasing incidence of localised renal cell carcinoma (RCC) over the last 3 decades and controversy over mortality rates have prompted reassessment of current treatment.
Prognostic Factors and Predictive Models in RCC
06/07/2012
The natural history of renal cell carcinoma (RCC) is highly unpredictable. Small renal masses may be accompanied by metastatic disease. Conversely, patients with locally advanced disease may enjoy long-term disease-free survival.
Current Pathology Keys of Renal Cell Carcinoma
06/07/2012
The conclusions reached by the ICUD-EAU 2010 International Consultation on Kidney Cancer emphasise the appropriate pathologic diagnosis of RCC in adults as a tool to approach patientsÂ’ prognosis and modulate current therapy. Further emphasis should be placed on defining risk groups of RCC and diagnostic features of unusual tumours such as familial RCC, translocation RCC, and tubular mucinous and spindle cell carcinoma.
Basic Research in Kidney Cancer
06/07/2012
To discuss advances in our understanding of the molecular basis of renal cancer, targeted therapies, renal cancer and immunity, and genetic factors and renal cell carcinoma (RCC).
The Epidemiology of Renal Cell Carcinoma
06/07/2012
Large collaborative studies with uniform data collection seem to be necessary to elucidate a complete list of established risk factors of RCC.
RCC: A Changing Paradigm With a Need for Consensus
06/07/2012
Kidney cancer remains important and functions as a model tumour type in oncology. Consequently, better understanding of the mechanisms of renal cancer development, utilisation of alternative therapies, and new development of effective targeted therapies make kidney cancer a hot topic for consultation.
Cancer Therapeutics Under Development To Watch
06/06/2012
I was able to look at the following very interesting therapeutics which are novel treatments that primarily target tumor escape pathways.
Oncolytic virotherapy for renal cell carcinoma
06/06/2012
Despite the development of novel targeted therapies, metastatic renal cell carcinoma (mRCC) remains an incurable disease. The known responsiveness of mRCC to immunotherapy and the molecular aberrations characteristic of this disease make it an attractive malignancy for treatment with oncolytic viruses (OVs), as these agents are capable of usurping common oncogenic signaling pathways and generating anti-tumor immune responses.
News Feed